Exosome Profiling Pinpoints Cancer Type.

Abstract:

:A study shows that analyzing the protein contents of exosomes and related extracellular vesicles can distinguish tumors from nearby noncancerous tissue, and profiling extracellular vesicle proteins obtained from plasma may also reveal cancer type. The results support using vesicle proteins for liquid biopsies.

journal_name

Cancer Discov

journal_title

Cancer discovery

authors

doi

10.1158/2159-8290.CD-NB2020-083

subject

Has Abstract

pub_date

2020-11-01 00:00:00

pages

1619

issue

11

eissn

2159-8274

issn

2159-8290

pii

2159-8290.CD-NB2020-083

journal_volume

10

pub_type

杂志文章
  • Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.

    abstract:UNLABELLED:Genetic approaches have shown that the p110β isoform of class Ia phosphatidylinositol-3-kinase (PI3K) is essential for the growth of PTEN-null tumors. Thus, it is desirable to develop p110β-specific inhibitors for cancer therapy. Using a panel of PI3K isoform-specific cellular assays, we screened a collectio...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-12-0003

    authors: Ni J,Liu Q,Xie S,Carlson C,Von T,Vogel K,Riddle S,Benes C,Eck M,Roberts T,Gray N,Zhao J

    更新日期:2012-05-01 00:00:00

  • A FATal Combination: Fibroblast-Derived Lipids and Cancer-Derived Autotaxin Promote Pancreatic Cancer Growth.

    abstract::In this issue of Cancer Discovery, Auciello and colleagues find that in the pancreatic cancer microenvironment activated fibroblasts secrete specific lipids that provide a source of biomass production and signaling molecules for cancer cells, fueling their proliferation and migration. Targeting of this stromal-tumor m...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-19-0273

    authors: Biffi G,Tuveson DA

    更新日期:2019-05-01 00:00:00

  • Intense Radiotherapy Slows Prostate Cancer Growth.

    abstract::Adding stereotactic ablative radiotherapy (SABR) to standard treatment slowed 6-month disease progression in men with hormone-sensitive metastatic prostate cancer, allowing them to delay androgen deprivation therapy, according to findings from the phase II ORIOLE trial. Larger studies are needed to determine if SABR, ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2020-034

    authors:

    更新日期:2020-06-01 00:00:00

  • BRCA1: a missing link in the Fanconi anemia/BRCA pathway.

    abstract::Domchek and colleagues provide a case report of a 28-year-old woman with congenital abnormalities, inherited ovarian cancer, and carboplatin hypersensitivity. Interestingly, the woman had validated germline mutations in both BRCA1 alleles. These findings further implicate BRCA1 in the Fanconi anemia/BRCA pathway and h...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-13-0044

    authors: D'Andrea AD

    更新日期:2013-04-01 00:00:00

  • "Super Trastuzumab" Extends PFS in Late-Line Breast Cancer.

    abstract::Margetuximab outperformed trastuzumab in a phase III, head-to-head trial of the two anti-HER2 agents among patients with HER2-positive metastatic breast cancer. The new antibody drug was engineered for enhanced immune activity against HER2-expressing tumor cells. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2019-069

    authors:

    更新日期:2019-08-01 00:00:00

  • Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.

    abstract::The quest for tumor-associated antigens (TAA) and neoantigens is a major focus of cancer immunotherapy. Here, we combine a neoantigen prediction pipeline and human leukocyte antigen (HLA) peptidomics to identify TAAs and neoantigens in 16 tumors derived from seven patients with melanoma and characterize their interact...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-17-1418

    authors: Kalaora S,Wolf Y,Feferman T,Barnea E,Greenstein E,Reshef D,Tirosh I,Reuben A,Patkar S,Levy R,Quinkhardt J,Omokoko T,Qutob N,Golani O,Zhang J,Mao X,Song X,Bernatchez C,Haymaker C,Forget MA,Creasy C,Greenberg P,

    更新日期:2018-11-01 00:00:00

  • Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.

    abstract::E3 ubiquitin ligases are of interest as drug targets for their ability to regulate protein stability and function. The oncogene Mdm2 is an attractive E3 ligase to target, as it is the key negative regulator of the tumor suppressor p53, which controls the transcription of genes involved in cell fate. Overexpression of ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-11-0104

    authors: Herman AG,Hayano M,Poyurovsky MV,Shimada K,Skouta R,Prives C,Stockwell BR

    更新日期:2011-09-01 00:00:00

  • Panel OKs CAR T Therapy for Leukemia.

    abstract::An expert panel recommended approval of Novartis's experimental chimeric antigen T-cell therapy, tisagenlecleucel, for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. The therapy would be the first of its kind approved for cancer and has the potential to transform standard of...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-108

    authors:

    更新日期:2017-09-01 00:00:00

  • Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.

    abstract::Venetoclax-based therapy can induce responses in approximately 70% of older previously untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well as relapse following initial response demonstrates the need for a deeper understanding of resistance mechanisms. In the present study, we rep...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-19-0710

    authors: Pei S,Pollyea DA,Gustafson A,Stevens BM,Minhajuddin M,Fu R,Riemondy KA,Gillen AE,Sheridan RM,Kim J,Costello JC,Amaya ML,Inguva A,Winters A,Ye H,Krug A,Jones CL,Adane B,Khan N,Ponder J,Schowinsky J,Abbott D,Ham

    更新日期:2020-04-01 00:00:00

  • Two Worlds Collide: Unraveling the Role of the Immune System in BRAF-MEK Inhibitor Responses.

    abstract::Although BRAF-MEK inhibition can enhance the immune recognition of melanoma cells, the mechanisms that underlie this remain poorly defined. In this issue of Cancer Discovery, Erkes and colleagues present new data showing that BRAF-MEK inhibition activates pyroptosis in melanoma cells through gasdermin E cleavage, lead...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-19-1441

    authors: Smalley KSM

    更新日期:2020-02-01 00:00:00

  • YY1 Facilitates Enhancer-Promoter Contacts to Promote Gene Expression.

    abstract::YY1 preferentially occupies active enhancers and promoters and forms dimers to promote DNA looping. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-RW2017-233

    authors:

    更新日期:2018-02-01 00:00:00

  • MET Promotes Antitumor Neutrophil Recruitment and Cytotoxicity.

    abstract::MET is critical for antitumor neutrophil infiltration to HGF-secreting tumors and inflammatory sites. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2015-097

    authors:

    更新日期:2015-07-01 00:00:00

  • Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers.

    abstract::Translational data on chimeric antigen receptor (CAR) T-cell trials indicate that the presence of naïve T cells in the premanufacture product is important to clinical response and persistence. In anticipation of developing CAR trials for other tumors, we investigated the T-cell distribution from children with solid tu...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-18-1314

    authors: Das RK,Vernau L,Grupp SA,Barrett DM

    更新日期:2019-04-01 00:00:00

  • Anti-CD22 CAR Therapy Leads to ALL Remissions.

    abstract::In a first-in-human trial of an anti-CD22 chimeric antigen receptor T-cell therapy in children and young adults with relapsed and refractory acute lymphocytic leukemia, researchers found that the immunotherapeutic approach was not only feasible and safe, but also effective, leading to remissions in most patients. Infu...

    journal_title:Cancer discovery

    pub_type:

    doi:10.1158/2159-8290.CD-NB2017-001

    authors:

    更新日期:2017-02-01 00:00:00

  • Antibody-Drug Conjugate Kills Neuroblastoma Cells.

    abstract::Researchers have developed an antibody-drug conjugate with the potential to treat neuroblastoma. The agent targets ALK, which is found on neuroblastoma cells but not healthy cells, delivering a drug that causes DNA cross-links. Researchers have found that the antibody-drug conjugate kills ALK-expressing cells in vitro...

    journal_title:Cancer discovery

    pub_type: 评论,新闻

    doi:10.1158/2159-8290.CD-NB2019-052

    authors:

    更新日期:2019-06-01 00:00:00

  • High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.

    abstract:UNLABELLED:Knowledge of "actionable" somatic genomic alterations present in each tumor (e.g., point mutations, small insertions/deletions, and copy-number alterations that direct therapeutic options) should facilitate individualized approaches to cancer treatment. However, clinical implementation of systematic genomic ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-11-0184

    authors: Wagle N,Berger MF,Davis MJ,Blumenstiel B,Defelice M,Pochanard P,Ducar M,Van Hummelen P,Macconaill LE,Hahn WC,Meyerson M,Gabriel SB,Garraway LA

    更新日期:2012-01-01 00:00:00

  • Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

    abstract:UNLABELLED:Although it is known that mTOR complex 2 (mTORC2) functions upstream of Akt, the role of this protein kinase complex in cancer is not well understood. Through an integrated analysis of cell lines, in vivo models, and clinical samples, we demonstrate that mTORC2 is frequently activated in glioblastoma (GBM), ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-11-0124

    authors: Tanaka K,Babic I,Nathanson D,Akhavan D,Guo D,Gini B,Dang J,Zhu S,Yang H,De Jesus J,Amzajerdi AN,Zhang Y,Dibble CC,Dan H,Rinkenbaugh A,Yong WH,Vinters HV,Gera JF,Cavenee WK,Cloughesy TF,Manning BD,Baldwin AS,Mi

    更新日期:2011-11-01 00:00:00

  • PI3K and STAT3: a new alliance.

    abstract:UNLABELLED:Recent proteomic data have uncovered an interdependence of PI3K and STAT3. In PI3K-tranformed murine cells, STAT3 is phosphorylated on Y705 and activated in a PI3K-dependent manner. Dominant negative STAT3 interferes with PI3K-induced oncogenic transformation. Phosphorylation of STAT3 in PI3K-transformed mur...

    journal_title:Cancer discovery

    pub_type: 杂志文章,评审

    doi:10.1158/2159-8290.CD-11-0218

    authors: Vogt PK,Hart JR

    更新日期:2011-11-01 00:00:00

  • Midostaurin Gets FDA Nod for AML.

    abstract::The FDA has approved the small-molecule inhibitor midostaurin in combination with chemotherapy to treat acute myeloid leukemia. It is the first approved drug for the disease that specifically targets FLT3 mutations, which occur in about a quarter of all AML cases and are associated with particularly poor outcomes. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-072

    authors:

    更新日期:2017-07-01 00:00:00

  • First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.

    abstract::Targeting the ataxia telangiectasia and RAD3-related (ATR) enzyme represents a promising anticancer strategy for tumors with DNA damage response (DDR) defects and replication stress, including inactivation of ataxia telangiectasia mutated (ATM) signaling. We report the dose-escalation portion of the phase I first-in-h...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-20-0868

    authors: Yap TA,Tan DSP,Terbuch A,Caldwell R,Guo C,Goh BC,Heong V,Haris NRM,Bashir S,Drew Y,Hong DS,Meric-Bernstam F,Wilkinson G,Hreiki J,Wengner AM,Bladt F,Schlicker A,Ludwig M,Zhou Y,Liu L,Bordia S,Plummer R,Lagkadin

    更新日期:2020-09-28 00:00:00

  • BET Proteins as Targets for Anticancer Treatment.

    abstract::Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that regulate gene expression and are involved in cancer pathogenesis. Over the last years, several BET inhibitors have been developed and clinically tested. Results from the first clinical trials show limited single-agent activity in a small s...

    journal_title:Cancer discovery

    pub_type: 杂志文章,评审

    doi:10.1158/2159-8290.CD-17-0605

    authors: Stathis A,Bertoni F

    更新日期:2018-01-01 00:00:00

  • Second-generation ALK inhibitors: filling the non "MET" gap.

    abstract::Ceritinib and other second-generation inhibitors have demonstrated promising anticancer activity in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Specifically, they can overcome resistance due to certain gatekeeper mutations acquired following crizotinib exposure. These agents now provi...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-14-0410

    authors: Ramalingam SS,Khuri FR

    更新日期:2014-06-01 00:00:00

  • How does multistep tumorigenesis really proceed?

    abstract::Identifying the cancer cells-of-origin is of great interest, as it holds the potential to elucidate biologic mechanisms inherent in the normal cell state that have been co-opted to drive the oncogenic cell state. An emerging concept, proposed here, states that cancer stem cells, key players in cancer initiation and me...

    journal_title:Cancer discovery

    pub_type: 杂志文章,评审

    doi:10.1158/2159-8290.CD-14-0788

    authors: Chaffer CL,Weinberg RA

    更新日期:2015-01-01 00:00:00

  • Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges.

    abstract::An increasing number of anticancer therapeutic agents target specific mutant proteins that are expressed by many different tumor types. Recent evidence suggests that the selection of patients whose tumors harbor specific genetic alterations identifies the subset of patients who are most likely to benefit from the use ...

    journal_title:Cancer discovery

    pub_type: 杂志文章,评审

    doi:10.1158/2159-8290.CD-11-0110

    authors: MacConaill LE,Van Hummelen P,Meyerson M,Hahn WC

    更新日期:2011-09-01 00:00:00

  • Chemotherapy Efficacy Is Dependent upon p53 Dynamics.

    abstract::Drug-induced apoptosis occurs after cells reach a p53 threshold level, which increases over time. ...

    journal_title:Cancer discovery

    pub_type: 信件

    doi:10.1158/2159-8290.CD-RW2016-077

    authors:

    更新日期:2016-06-01 00:00:00

  • First Comprehensive Companion Diagnostic OK'd.

    abstract::The FDA has approved F1CDx, a comprehensive companion diagnostic test that can detect genetic alterations and two genomic signatures in any type of solid tumor. Patients with five common types of advanced cancer can be matched to one of 17 targeted therapies with this single test. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-182

    authors:

    更新日期:2018-03-01 00:00:00

  • Tweaking Transcription to Stop AML Cell Growth.

    abstract::A new compound with anti-leukemia activity perturbs gene transcription by modulating super-enhancer activity. ...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2015-149

    authors:

    更新日期:2015-12-01 00:00:00

  • Tucatinib Impresses in Breast Cancer.

    abstract::Recent results suggest that tucatinib, when combined with trastuzumab and capecitabine, is effective in patients with locally advanced inoperable or metastatic HER2-positive breast cancer who have received prior therapies: In a phase II trial, the drug extended overall survival and progression-free survival compared w...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2019-135

    authors:

    更新日期:2020-01-01 00:00:00

  • Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the Combination.

    abstract::In this issue of Cancer Discovery, Diab and colleagues demonstrate in a phase I trial enrolling 38 patients diagnosed with advanced solid tumors that combining the pegylated IL2 bempegaldesleukin with an anti-PD-1 mAb is safe, with an overall response rate of 59.5%. This compelling clinical activity is supported by th...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-20-0786

    authors: Rouanne M,Zitvogel L,Marabelle A

    更新日期:2020-08-01 00:00:00

  • mTOR inhibition, the second generation: ATP-competitive mTOR inhibitor initiates unexpected receptor tyrosine kinase-driven feedback loop.

    abstract::mTOR inhibition with the ATP-competitive kinase inhibitor AZD8055 induces receptor tyrosine kinase-dependent feedback activation of AKT. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-11-0157

    authors: Keniry M,Parsons R

    更新日期:2011-08-01 00:00:00